Objective
to assess the effectiveness and safety of transcatheter mitral valve repair (TMVR) with MitraClip in patients with heart failure
Study
randomised, multicentre, open-label
Population
patients with heart failure and severe secondary mitral regurgitation, symptomatic despite maximal therapy
Endpoints
primary effectiveness endpoint: all heart failure hospitalisation within 24 months. Primary safety end point; freedom from device-related complications at 12 months
Conclusion
among patients with heart failure and mitral regurgitation who were symptomatic despite maximal medical therapy TMVR with MitraClip was safe and effective as reducing heart failure hospitalisation
Stone et al. N Eng J Med. 2018;379:2307-18